Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy

European Journal of Neurology

Volumn 8, Issue SUPPL. 5, 2001, Pages 30-39

  Graham, H K ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Botulinum toxin type A; Cerebral palsy; Deformity; Orthopaedic surgery; Spasticity

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ANIMAL; CEREBRAL PALSY; CLASSIFICATION; HEMIPLEGIA; HIP; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; REVIEW; SKELETAL MUSCLE; SPASTICITY;

ANIMALS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; COMBINED MODALITY THERAPY; HEMIPLEGIA; HIP; HUMANS; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS;

EID: 18744401900     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2001.00036.x     Document Type: Article

References (4)

1. Albright AL (1996). Intrathecal baclofen in cerebral palsy movement disorders. J Child Neural 11:S29-S35.
2. Banwood S, Baillieu C, Boyd R et al. (2000). Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Der Med Child Neural 42:116-121.
3. Borton DC, Walker K, Pirpiris M, Nattrass GR, Graham HK (2001). Isolated calf lengthening in cerebral palsy-outcome analysis of risk factors. J Bone Joint Surg (Br) 83: 364-370.
4. Boyd R, Barwood SA, Baillieu CE, Graham HK (1998a). Validity of a clinical measure of spasticity in children with cerebral palsy in a randomized clinical trial. American Academy of Cerebral Palsy San Antonio (AACPDM) [Abstract]. Dev Med Child Neural 40:7.